Table 2.
Adverse events
| Adverse event, n (%) | All grades | Grade 1 | Grade 2 | Grade 3 | Grade 4 |
|---|---|---|---|---|---|
| All events | 7 (100) | 7 (100) | 7 (100) | 7 (100) | 3 (43) |
| Alopecia | 7 (100) | 0 | 7 (100) | 0 | 0 |
| Hypertension | 6 (86) | 0 | 3 (43) | 3 (43)a | 0 |
| Decreased appetite | 6 (86) | 3 (43) | 3 (43) | 0 | 0 |
| Nausea | 6 (86) | 4 (57) | 2 (29) | 0 | 0 |
| Peripheral sensory neuropathy | 6 (86) | 3 (43) | 3 (43) | 0 | 0 |
| Malaise | 4 (57) | 2 (29) | 2 (29) | 0 | 0 |
| Dysgeusia | 4 (57) | 2 (29) | 2 (29) | 0 | 0 |
| Neutrophil count decreased | 3 (43) | 0 | 1 (14) | 1 (14) | 1 (14) |
| Stomatitis | 3 (43) | 1 (14) | 2 (29) | 0 | 0 |
| Upper respiratory tract infection | 3 (43) | 0 | 3 (43) | 0 | 0 |
| Constipation | 3 (43) | 1 (14) | 2 (29) | 0 | 0 |
| Nail discoloration | 3 (43) | 3 (43) | 0 | 0 | 0 |
| Flushing | 3 (43) | 3 (43) | 0 | 0 | 0 |
| Neutropenia | 2 (29) | 0 | 0 | 1 (14) | 1 (14) |
| Anemia | 2 (29) | 1 (14) | 0 | 1 (14) | 0 |
| Dehydration | 2 (29) | 0 | 1 (14) | 1 (14) | 0 |
| Proteinuria | 2 (29) | 0 | 1 (14) | 1 (14)a | 0 |
| Blood creatinine increased | 2 (29) | 0 | 2 (29) | 0 | 0 |
| Vomiting | 2 (29) | 1 (14) | 1 (14) | 0 | 0 |
| Fatigue | 2 (29) | 1 (14) | 1 (14) | 0 | 0 |
| Back pain | 2 (29) | 1 (14) | 1 (14) | 0 | 0 |
| Hemorrhoids | 2 (29) | 2 (29) | 0 | 0 | 0 |
| Infusion-site pain | 2 (29) | 2 (29) | 0 | 0 | 0 |
| Insomnia | 2 (29) | 2 (29) | 0 | 0 | 0 |
| Febrile neutropenia | 1 (14) | 0 | 0 | 0 | 1 (14)a |
| Diarrhea | 1 (14) | 0 | 0 | 1 (14) | 0 |
| Hyponatremia | 1 (14) | 0 | 0 | 1 (14) | 0 |
| Gingivitis | 1 (14) | 0 | 0 | 1 (14) | 0 |
| Pyelonephritis | 1 (14) | 0 | 0 | 1 (14) | 0 |
| Infusion-site phlebitis | 1 (14) | 0 | 1 (14) | 0 | 0 |
| Wound infection | 1 (14) | 0 | 1 (14) | 0 | 0 |
| Herpes zoster | 1 (14) | 0 | 1 (14) | 0 | 0 |
| Gamma glutamyltransferase increased | 1 (14) | 0 | 1 (14) | 0 | 0 |
| Ingrowing nail | 1 (14) | 0 | 1 (14) | 0 | 0 |
| Urinary tract infection | 1 (14) | 0 | 1 (14) | 0 | 0 |
| Weight decreased | 1 (14) | 0 | 1 (14) | 0 | 0 |
| Pruritus | 1 (14) | 1 (14) | 0 | 0 | 0 |
| Rash maculopapular | 1 (14) | 1 (14) | 0 | 0 | 0 |
| Abdominal pain upper | 1 (14) | 1 (14) | 0 | 0 | 0 |
| Infusion-site edema | 1 (14) | 1 (14) | 0 | 0 | 0 |
| Edema | 1 (14) | 1 (14) | 0 | 0 | 0 |
| Oral herpes | 1 (14) | 1 (14) | 0 | 0 | 0 |
| Aspartate aminotransferase increased | 1 (14) | 1 (14) | 0 | 0 | 0 |
| Alanine aminotransferase increased | 1 (14) | 1 (14) | 0 | 0 | 0 |
| Blood pressure increased | 1 (14) | 1 (14) | 0 | 0 | 0 |
| Arthralgia | 1 (14) | 1 (14) | 0 | 0 | 0 |
| Myalgia | 1 (14) | 1 (14) | 0 | 0 | 0 |
| Hot flush | 1 (14) | 1 (14) | 0 | 0 | 0 |
| Pharyngeal inflammation | 1 (14) | 1 (14) | 0 | 0 | 0 |
| Periodontal disease | 1 (14) | 1 (14) | 0 | 0 | 0 |
| Abdominal discomfort | 1 (14) | 1 (14) | 0 | 0 | 0 |
| Fecal incontinence | 1 (14) | 1 (14) | 0 | 0 | 0 |
| Chills | 1 (14) | 1 (14) | 0 | 0 | 0 |
| Face edema | 1 (14) | 1 (14) | 0 | 0 | 0 |
| Infusion-site induration | 1 (14) | 1 (14) | 0 | 0 | 0 |
| Infusion-site swelling | 1 (14) | 1 (14) | 0 | 0 | 0 |
| Edema peripheral | 1 (14) | 1 (14) | 0 | 0 | 0 |
| Periodontitis | 1 (14) | 1 (14) | 0 | 0 | 0 |
| Tinea infection | 1 (14) | 1 (14) | 0 | 0 | 0 |
| Headache | 1 (14) | 1 (14) | 0 | 0 | 0 |
| Dizziness | 1 (14) | 1 (14) | 0 | 0 | 0 |
| Cough | 1 (14) | 1 (14) | 0 | 0 | 0 |
| Contusion | 1 (14) | 1 (14) | 0 | 0 | 0 |
| Excoriation | 1 (14) | 1 (14) | 0 | 0 | 0 |
| Fall | 1 (14) | 1 (14) | 0 | 0 | 0 |
| Anxiety | 1 (14) | 1 (14) | 0 | 0 | 0 |
| Tinnitus | 1 (14) | 1 (14) | 0 | 0 | 0 |
aAdverse event of special interest for bevacizumab.